Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.34 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16909689 | 0.94 | ALKBH1 (0.34) | TNFALKBH1RIPK1SLC2A1MCHR1 | |
| SCHEMBL15415732 | 0.93 | ALKBH1 (0.36) | TNFALKBH1RIPK1SLC2A1MCHR1 | |
| SCHEMBL16909817 | 0.93 | ALKBH1 (0.36) | TNFALKBH1RIPK1SLC2A1 | |
| SCHEMBL16909715 | 0.87 | ALKBH1 (0.35) | TNFALKBH1SLC2A1 | |
| SCHEMBL16909474 | 0.86 | ALKBH1 (0.38) | TNFALKBH1RIPK1SLC2A1EPHB3 | |
| SCHEMBL16909425 | 0.84 | TNF (0.36) | TNFALKBH1 | |
| SCHEMBL16874416 | 0.82 | CDK9 (0.35) | TNFALKBH1 | |
| SCHEMBL16909880 | 0.81 | SLC2A1 (0.37) | TNFALKBH1SLC2A1MCHR1EPHB3 | |
| SCHEMBL16909751 | 0.80 | TNF (0.39) | TNFALKBH1SLC2A1 | |
| SCHEMBL16909697 | 0.79 | ALKBH1 (0.38) | TNFALKBH1RIPK1SLC2A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | TNF 1/4885ALKBH1 4341/4885RIPK1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.